The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target

Cancer and Metastasis Reviews

Volumn 17, Issue 2, 1998, Pages 187-194

  Blancher, Christine ^a   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Angiogenesis; bHLH PAS proteins; EPAS 1; Glycolysis; HIF 1; Hypoxia

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYTOTOXIC AGENT; DNA BINDING PROTEIN; HELIX LOOP HELIX PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN EPAS 1; TIRAPAZAMINE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

CANCER GROWTH; DRUG TARGETING; GENE THERAPY; HYPOXIA; ONCOGENE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; REVIEW; TUMOR VASCULARIZATION;

ANIMALS; CELL HYPOXIA; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 0031823016     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006002419244     Document Type: Review

References (30)

1. Wenger RH, Gassman M: Oxygen(es) and the hypoxia-inducible factor-I. Biol Chem 378: 609-616, 1997
2. Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor-1 is a basic-helix-loop-helix-pas heterodimer regulated by cellular O-2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995
3. Reyes H. S. R-P. Hankinson O: Ah receptor nuclear translocator protein (ARNT) as a component of the DNA binding form of the Ah receptor. Science 256: 1193-1195, 1992
4. Hahn ME, Karchner SI, Shapiro MA, Perera SA: Molecular evolution of 2 vertebrate aryl-hydrocarbon (dioxin) receptors (ahr1 and ahr2) and the pas family. Proc Natl Acad Sci USA 94: 13743-13748, 1997
5. Schmidt JV, Bradfield CA: Ah receptor signalling pathways. Annu Rev Cell Dev Biol 12: 55-89, 1996
6. Zelzer E, Wappner P, Shilo BZ: The pas domain confers target gene specificity of drosophila bhlh/pas proteins. Genes Dev 11: 2079-2089, 1997
7. Jiang BJ, Semenza GL, Bauer C, Marti HH: Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 271: C1172-C1180, 1996
8. Semenza GL: Transcriptional regulation by hypoxia-inducible factor 1. Molecular mechanisms of oxygen homeostasis. Trends Cardiovasc Med 6: 151-157, 1996
9. Bunn HF, Poyton RO: Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 76: 839-885, 1996
10. Gleadle JM, Ebert BL, Ratcliffe PJ: Deiphenylene iodonium inhibits the induction of erythropoietin and other mammalian genes by hypoxia: Implications for the mechanism of oxygen sensing. Eur J Biochem 234: 92-99, 1995
11. Salceda S, Caro J: Hypoxia-inducible factor 1 alpha (hif-1 alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions - its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-22647, 1997
12. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L: Activation of hypoxia-inducible factor 1-alpha-posttranscriptional regulation and conformational change by recruitment of the arnt transcription factor. Proc Natl Acad Sci USA 94: 5667-5672, 1997
13. Tian H, McKnight SL, Russel DW: Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11: 72-82, 1997
14. Shikama N, Lyon J, La Thangue NB: The p300/CBP family: Integrating signals with transcription factors and chromatin. Trends in Cell Biology 7: 230-236, 1997
15. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF, Livingston DM: An essential role for p300/cbp in the cellular-response to hypoxia. Proc Natl Acad Sci USA 93: 12969-12973, 1996
16. Firth JD, Ebert BL, Ratcliffe PJ: Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 270: 21021-21027, 1995
17. Levy AP, Levy NS, Iliopoulos O, Jiang C, Kaelin WG, Goldberg MA: Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney International 51: 575-578, 1997
18. Levy AP, Levy NS, Goldberg MA: Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J Biol Chem 271: 25492-25497, 1996
19. Damert A, Ikeda E, Risau W: Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia- induced transcriptional activation of vascular-endothelial growth-factor expression in c6 glioma-cells. Biochem J 327: 419-423, 1997
20. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ: Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth-factor expression. Cancer Res 56: 3436-3440, 1996
21. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS: Mutant ras oncogenes up-regulate vegf/ vpf expression - implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995
22. Petit AMV, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS: Neutralizing antibodies against epidermal growth-factor and erbb-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth-factor production by tumor-cells in-vitro and in-vivo-angiogenic implications for signal-transduction therapy of solid tumours. Am J Pathol 151: 1523-1530, 1997
23. Griffiths L, Dachs GU, Bicknell R, Harris AL, Stratford IJ: The influence of oxygen-tension and pH on the expression of platelet-derived endothelial-cell growth-factor thymidine phosphorylase in human breast-tumor cells grown in-vitro and in-vivo. Cancer Res 57: 570-572, 1997
24. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene-expression in solid tumours and influences both angiogenesis and tumor-growth. Proc Natl Acad Sci USA 94: 8104-8109, 1997
25. Adams GE, Hasan NM, Joiner MC: Radiation, hypoxia and genetic stimulation-implications for future therapies. Radiother Oncol 44: 101-109, 1997
26. Wouters BG, Brown JM: Cells at intermediate oxygen levels can be more important than the hypoxic fraction in determining tumor response to fractionated radiotherapy. Radiat Res 147: 541-550, 1997
27. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38: 285-289, 1997
28. Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, Stratford IJ: Overexpression of human NADPH: cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 76: 1338-1347, 1997
29. Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KMS, Stratford IJ, Harris AL: Targeting gene-expression to hypoxic tumor-cells. Nature Med 3: 515-520, 1997
30. Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN, Brem H: Potentiation of cytotoxic cancer therapies by tnp-470 alone and with other anti-angiogenic agents. Int J Cancer 57: 920-925, 1994